Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Barclays PLC boosted its stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 325.1% during the third quarter, Holdings Channel reports. The institutional investor owned 7,018 shares of the company’s stock after buying an additional 5,367 shares during the period. Barclays PLC’s holdings in Telomir Pharmaceuticals were worth $45,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock worth $1,533,000 after purchasing an additional 172,382 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals during the second quarter worth approximately $241,000. Suncoast Equity Management increased its stake in Telomir Pharmaceuticals by 109.9% during the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after acquiring an additional 26,803 shares during the period. State Street Corp raised its holdings in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock valued at $232,000 after acquiring an additional 17,967 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC lifted its position in shares of Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after acquiring an additional 9,950 shares during the period.

Telomir Pharmaceuticals Trading Up 5.9 %

Shares of Telomir Pharmaceuticals stock opened at $5.03 on Friday. The firm’s 50-day moving average price is $4.69 and its two-hundred day moving average price is $4.79. Telomir Pharmaceuticals, Inc. has a 12-month low of $3.11 and a 12-month high of $20.72.

Telomir Pharmaceuticals (NASDAQ:TELO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.20) EPS for the quarter. Equities research analysts anticipate that Telomir Pharmaceuticals, Inc. will post -0.54 EPS for the current year.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.